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New research is needed to improve HPV vaccines. Several challenges need to be resolved before HPV vaccination can be implemented in 
developing countries. It involves one of the most controversial issues in recent times: teenage sexual health, therefore it is needed to increase 
the efforts to make the population be informed.  
However, up to now, Gardasil and Cervarix have been proved to be totally safe and effective after millions of doses administrated around the 
world, no serious event was causally related to vaccination. Maybe at the moment of the introduction of the vaccine there were not evidence 
enough to take it as a priority but current results are positive.   
 
 
 
 
 
 
The Human Papilomavirus (HPV) is a group of DNA viruses that can cause warts and 
other subclinical infections which lead to cervical, vulva, vagina and anus cancer in 
women, or anus and penis cancer in men. In most cases HPV goes away by itself before 
it causes any health problems. Recently, new possibilities in cervical cancer prevention 
and immunotherapy have been created. We are going to review these different types of 
vaccines and consider all the possible arguments to accept or reject them. 
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Prophylactic vaccines 
Designed to prevent HPV infection and ano-genital cancer in women and men between 
9 and 45 years in several countries.  
 
 
Therapeutic vaccines 
 
 
 
 
Virus description:   
 Papilomaviridae family. 
 Double stranded DNA, no envelope and icosahedral symmetry.  
 Early and late genes (E1-E7, L1 and L2).  
More than 40 types of HPV can infect the genital area of males and females. 
 Worldwide prevalence: 10%. 
 
 
 
 
 
 
 
 
 
 
 
Infection and transmission: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Genital HPV penetrate in lesions of the 
epithelium and infect squamous epithelial 
cells.  
In most cases, HPV infection is self-limited 
and asymptomatic. In other cases it can lead 
to cervical cancer or genital warts.  
Most sexually active population will be in 
contact with the virus at some point of their 
lives.  
 AIDS increases the chances of becoming 
infected with HPV. No association between 
mother’s HPV status at pregnancy and child’s 
HPV status.  
Prevention: use of condoms and vaccination. 
 
• HPV classification: low risk (ex: types 6 and 11), intermediate 
and high risk  (ex: types 16, 18, 31 and 45). 
•HPV infection is necessary to develop cervical cancer. 
•Types 16 and 18 cause 70% of the cervical cancer cases. 
•Two predominant forms: squamous carcinoma (80% of the 
cases, mostly associated to type 16)and adenocarcinoma (type 
16, 18 and 45). 
•Cervical Cancer classification: 
 
Cervarix™- bivalent vaccine. It protects 
against HPV-16 and 18. Produced by 
GlaxoSmithkline. Based on VLP 
produced in Trichoplusia ni Rix4446, 
using a baculovirus as expression 
vector. Adjuvant: ASO4. 
Intramuscularly administrated in three 
doses (month 0, 1 and 6). 
 
Gardasil™ - quadrivalent vaccine. It 
protects against HPV types 16, 18, 6 
and 11.  Produced by Merck. Based on 
VLP produced in yeast Saccharomyces 
cerevisiae. Adjuvant: aluminum 
hydroxyphospate sulfate. 
Administrated intramuscularly in three 
doses (month 0, 2 and 6). 
 
*Contraindicated for persons with history of allergic reaction to the vaccine or to 
any of its components and for women during pregnancy. No contraindication for 
immunosuppressed individuals but immunogenicity is not guaranteed.  
*Few and mild side effects. 
 
Pros Cons 
– The vaccine guards against four of the HPV 
strains, two of them have been shown to cause 
70% of cervical cancer cases and the other two 
linked to 90% of the genital warts cases. 
  
– The vaccine has been licensed by the FDA and 
has been deemed safe and effective by the CDC. 
 
– HPV vaccines are recommended by several 
important committees.  
 
– Cross-protection against other HPV types. 
– High cost associated precludes its widespread 
use in the developing countries. 
 
– Benefit or cost-effectiveness of vaccinating 
males is unknown. 
  
– Twelve years is not the appropriate age to 
begin sex education. 
 
– Some parents were unwilling to give too many 
vaccines to their children.  
 
– Continued screening is necessary because the 
vaccine does not prevent other cancer-causing 
strands of HPV or other causes of cervical cancer. 
 
– It may be too early to presume long-term 
efficacy and cost-effectiveness. 
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Future challenges and conclusions 
Designed to treat preexistent cancer by 
means of improving natural immune 
response against the tumor.  
Many different types of therapeutic 
vaccines are being developed and studied 
in phase I and II clinical trials.  
Strategies: live vector based, protein or 
peptide based, nucleic acid (DNA/RNA) 
based or VLP. Adjuvant: TLR agonists or 
cytokines.  
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